BACKGROUND: Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure. METHODS: From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center. One hundred and forty-three patients were transplanted for hepatocellular carcinoma (HCC) and in 22 cases patients were treated with Y90-RE before liver transplantation (LT), of them 4 with macrovascular invasion were included in this study. RESULTS: The four patients had a complete response for the thrombosis, and were included in the waiting list within the Milan criteria. Means interval time between Y90-RE and LT was 15.86 months. No patient death was observed at Y90-RE procedure or at LT. We obtain a free-survival of 39.1 (range, 6-76) months. In all four cases the complete thrombosis regression was observed. CONCLUSIONS: We reported a short series of patients transplanted after Y90-RE in patients with BCLC stage C. In our experience we achieved acceptable overall and disease-free survival. Eventually, Y90-RE seems to have a place in the downstaging strategy for LT candidates.
BACKGROUND:Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure. METHODS: From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center. One hundred and forty-three patients were transplanted for hepatocellular carcinoma (HCC) and in 22 cases patients were treated with Y90-RE before liver transplantation (LT), of them 4 with macrovascular invasion were included in this study. RESULTS: The four patients had a complete response for the thrombosis, and were included in the waiting list within the Milan criteria. Means interval time between Y90-RE and LT was 15.86 months. No patientdeath was observed at Y90-RE procedure or at LT. We obtain a free-survival of 39.1 (range, 6-76) months. In all four cases the complete thrombosis regression was observed. CONCLUSIONS: We reported a short series of patients transplanted after Y90-RE in patients with BCLC stage C. In our experience we achieved acceptable overall and disease-free survival. Eventually, Y90-RE seems to have a place in the downstaging strategy for LT candidates.
Entities:
Keywords:
Barcelona Clinic Liver Cancer (BCLC); Yttrium; downstaging; hepatocellular carcinoma (HCC); liver transplantation (LT); macrovascular invasion; radioembolization
Authors: Lidia Strigari; Rosa Sciuto; Sandra Rea; Livio Carpanese; Giuseppe Pizzi; Antonella Soriani; Giuseppe Iaccarino; Marcello Benassi; Giuseppe Maria Ettorre; Carlo Ludovico Maini Journal: J Nucl Med Date: 2010-08-18 Impact factor: 10.057
Authors: Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem Journal: Cardiovasc Intervent Radiol Date: 2006 Jul-Aug Impact factor: 2.740
Authors: R J Lewandowski; L M Kulik; A Riaz; S Senthilnathan; M F Mulcahy; R K Ryu; S M Ibrahim; K T Sato; T Baker; F H Miller; R Omary; M Abecassis; R Salem Journal: Am J Transplant Date: 2009-06-22 Impact factor: 8.086
Authors: Giuseppe Maria Ettorre; Giovanni Battista Levi Sandri; Andrea Laurenzi; Marco Colasanti; Roberto Luca Meniconi; Raffaella Lionetti; Roberto Santoro; Pasquale Lepiane; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Rita Golfieri; Gianpiero D'Offizi; Adriano M Pellicelli; Mario Antonini; Giovanni Vennarecci Journal: World J Surg Date: 2017-01 Impact factor: 3.352
Authors: Laura M Kulik; Bassel Atassi; Lodewijk van Holsbeeck; Tameem Souman; Robert J Lewandowski; Mary F Mulcahy; Russell D Hunter; Albert A Nemcek; Michael M Abecassis; Kenneth G Haines; Riad Salem Journal: J Surg Oncol Date: 2006-12-01 Impact factor: 3.454
Authors: Luigi Bolondi; Andrew Burroughs; Jean-François Dufour; Peter R Galle; Vincenzo Mazzaferro; Fabio Piscaglia; Jean Luc Raoul; Bruno Sangro Journal: Semin Liver Dis Date: 2013-02-08 Impact factor: 6.115
Authors: Rehan Ali; Ahsun Riaz; Ahmed Gabr; Nadine Abouchaleh; Ronald Mora; Ali Al Asadi; Juan Carlos Caicedo; Michael Abecassis; Nitin Katariya; Haripriya Maddur; Laura Kulik; Robert J Lewandowski; Riad Salem Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-15 Impact factor: 9.236